Valuation: Gilead Sciences, Inc.

Market Cap 190B 169B 157B 142B 267B 17,987B 271B 1,875B 737B 9,412B 712B 697B 30,042B P/E 2026 *
-44.7x
P/E 2027 * 19x
Enterprise Value 211B 188B 174B 158B 297B 20,003B 301B 2,085B 820B 10,467B 792B 775B 33,408B EV / Sales 2026 *
6.87x
EV / Sales 2027 * 6.19x
Free-Float
99.89%
Yield 2026 *
2.15%
Yield 2027 * 2.19%
1 day+2.01%
1 week+3.29%
Current month+4.56%
1 month+3.90%
3 months+15.59%
6 months+12.05%
Current year+24.28%
1 week 29.84
Extreme 29.84
32.18
1 month 28.94
Extreme 28.94
32.18
Current year 23.97
Extreme 23.97
32.18
1 year 23.62
Extreme 23.62
32.18
3 years 20.08
Extreme 20.08
32.18
5 years 20.08
Extreme 20.08
32.18
10 years 20.08
Extreme 20.08
32.18
Manager TitleAgeSince
Chief Executive Officer 61 28/02/2019
Director of Finance/CFO 56 31/10/2019
Compliance Officer - 17/12/2025
Director TitleAgeSince
Director/Board Member 58 18/08/2016
Director/Board Member 73 31/12/2017
Director/Board Member 72 08/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
+2.01%+3.29% - - 190B
+3.49%+8.54%+59.89%+117.27% 1,106B
+2.19%-1.66%+34.23%+70.27% 612B
+2.26%+2.83%+25.92%+98.65% 500B
+2.58%+8.31%+37.43%+63.51% 367B
+3.25%+1.96%+74.90%+47.67% 354B
+1.85%+5.45%+21.38%+49.26% 286B
+1.76%+4.92%+0.48%+20.31% 256B
+3.29%+5.12%+46.90%+56.43% 230B
+2.25%+4.04%+27.44%+99.53% 190B
Average +1.34%+2.13%+36.51%+69.21% 433.35B
Weighted average by Cap. +0.79%+2.30%+41.69%+80.33%

Financials

2026 *2027 *
Net sales 30.73B 27.37B 25.38B 22.98B 43.22B 2,912B 43.83B 304B 119B 1,524B 115B 113B 4,864B 32.84B 29.25B 27.12B 24.56B 46.18B 3,112B 46.84B 324B 128B 1,628B 123B 121B 5,197B
Net income -4.26B -3.79B -3.52B -3.18B -5.99B -403B -6.07B -42.06B -16.53B -211B -15.97B -15.63B -674B 10.27B 9.15B 8.48B 7.68B 14.44B 973B 14.65B 101B 39.87B 509B 38.51B 37.71B 1,625B
Net Debt 21.27B 18.95B 17.57B 15.91B 29.92B 2,016B 30.34B 210B 82.6B 1,055B 79.79B 78.13B 3,367B 13.62B 12.13B 11.25B 10.18B 19.16B 1,291B 19.43B 135B 52.88B 675B 51.08B 50.02B 2,156B
Projected Income Statement - Annual - Gilead Sciences, Inc.
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
20/10/26 CA$31.43 +2.01% 1,822
19/10/26 CA$30.81 -1.75% 8,834
16/10/26 CA$31.36 -1.10% 3,069
15/10/26 CA$31.71 +2.75% 19,633
14/10/26 CA$30.86 +3.52% 6,071
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Gilead Sciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
153.07USD
Average target price
160.15USD
Spread / Average Target
+4.63%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Gilead Sciences, Inc.